Novo Nordisk shares tumble as weight-loss drug trial data disappoints

[Sunflower]

Much worse than tirz. I'm guessing that people didn't go to the highest dose because of side effects mainly.

22% is a great result, good news for all of us here that the market options are expanding

Also good news if you want to buy NOVO today at $85 like I did and later use the inevitable profits for more bootleg peptides.

 

[clayd]

People probably fell asleep at some point. Cagri seems to knock people out.

I definitely had a couple unplanned naps, and I am not a napper

 

[keangkong]

I definitely had a couple unplanned naps, and I am not a napper

I have trouble understanding why I, a user of tirzepatide, would want to switch to using cagrilintidine and semaglutide. Semaglutide alone, based on the studies, seems to have about the same side effects as tirzepatide. Anecdotal reports suggest semaglutide has more side effects. Why not stick with tirzepatide and achieve about the same level of weight loss. At least with reta anecdotes suggest that it causes greater weight loss than tirzepatide although the longer trials have yet to be completed.

 

[exploitedworkerbee]

I have trouble understanding why I, a user of tirzepatide, would want to switch to using cagrilintidine and semaglutide. Semaglutide alone, based on the studies, seems to have about the same side effects as tirzepatide. Anecdotal reports suggest semaglutide has more side effects. Why not stick with tirzepatide and achieve about the same level of weight loss. At least with reta anecdotes suggest that it causes greater weight loss than tirzepatide although the longer trials have yet to be completed.

Eventually tirz stops working the same. Cagri makes it feel like it did in the good ol days. But also makes many of us need a nap

 

[Sunflower]

I also bought Novo after the price drop because they're not a GLP-1 development company, they're a pharmaceutical development company. Like Lilly, they have other things in the pipeline that will eventually produce value for shareholders.

Yep, they are in stage 3 trials for Rybelsus (oral sema) to market for Alzheimer’s disease mitigation. Also stage 2 trials for Monlunabant, which targets the cannabinoid type 1 receptor, regulating appetite and metabolism. (A possible weight loss alternative for patient who can’t tolerate GLP1s or have food addictions).

Icodec, their 1x weekly insulin injection drug is approved in Europe, Japan, and Canada, and likely soon, the US.

 

[clayd]

I have trouble understanding why I, a user of tirzepatide, would want to switch to using cagrilintidine and semaglutide. Semaglutide alone, based on the studies, seems to have about the same side effects as tirzepatide. Anecdotal reports suggest semaglutide has more side effects. Why not stick with tirzepatide and achieve about the same level of weight loss. At least with reta anecdotes suggest that it causes greater weight loss than tirzepatide although the longer trials have yet to be completed.

I use tirz and stack a little cagri on day 5 to mitigate hunger

 

[keangkong]

I use tirz and stack a little cagri on day 5 to mitigate hunger

That makes more sense to me. I bet it works better than semaglutide + cagrilintidine.

 

[keangkong]

There already is. Unless something changes the FDA will attempt to shut down compounders (of Tirz) in the next 60-90 days and I think we can all agree that Sema is next.

It looks like it may last a little longer than that since the FDA has agreed to hold off enforcement against parties to the lawsuit against it until a judge rules on a motion for a preliminary injunction if the parties request one within two weeks. It is unknown whether the FDA would attempt to enforce against nonparty compounding pharmacies if it stopped enforcing against parties to the lawsuit.

 

[clayd]

That makes more sense to me. I bet it works better than semaglutide + cagrilintidine.

We'll see, I got a couple vials of cagrisema pretty cheap so I might try that on day 5 instead of just cagri in the next few weeks

 

[keangkong]

Don't forget that the US is still a filthy capitalist society that is compromised by pharma. Novo will make it cheaper and insurance companies will force patients to use it and approve very few prior authorizations for tirz. It's still possible it makes more money than Tirz in the US

Unlikely. They're still charging a great deal for semaglutide.

 

[noteablequotable]

I also bought Novo after the price drop because they're not a GLP-1 development company, they're a pharmaceutical development company. Like Lilly, they have other things in the pipeline that will eventually produce value for shareholders.

Looks like FDA just approved a drug for people with Hemophilia yesterday. I wonder if it will impact the stock at all.

https://www.thepharmaletter.com/fda-approves-novo-nordisks-alhemo

 

[Grannuaile]

There already is. Unless something changes the FDA will attempt to shut down compounders (of Tirz) in the next 60-90 days and I think we can all agree that Sema is next.

And let us not forget, Eli Lilly and Novo are learning their lessons. They’re not gonna let the compounders eat their lunch any longer. Eli Lilly is suing to categorize Reta as a biologic, not a drug, therefore no compounding can ever legitimately arise.

Once I read that, I knew I would be entering Greyland, and I am so happy to find myself here on the island of misfit toys with you lot. ;-)

 

[Grannuaile]

Looks like FDA just approved a drug for people with Hemophilia yesterday. I wonder if it will impact the stock at all.

https://www.thepharmaletter.com/fda-approves-novo-nordisks-alhemo

Dude. That is a serious ass newsletter - £820 a year - in British pound sterling no less.

 

[penewbie]

And let us not forget, Eli Lilly and Novo are learning their lessons. They’re not gonna let the compounders eat their lunch any longer. Eli Lilly is suing to categorize Reta as a biologic, not a drug, therefore no compounding can ever legitimately arise.

Once I read that, I knew I would be entering Greyland, and I am so happy to find myself here on the island of misfit toys with you lot. ;-)

EL doesn't have much of a legal case there, I wouldn't worry too much about that angle.

What's more likely in my eyes is that EL would make sure to be well positioned to meet demand for reta starting from day 1, either by pricing it prohibitively or massively increasing supply.

 

[nccane]

I unfortunately think Novo "disappears" and the stocks continue to tumble due to their us business. Many competitiors with amylin drugs coming eventually and tirz/reta.

They will only be competing on price before too long.

 

[JohnnyGobbs]

Novo is like the largest company in Europe. It’s not going anywhere.

 

[AndyPanda]

Yep, they are in stage 3 trials for Rybelsus (oral sema) to market for Alzheimer’s disease mitigation. Also stage 2 trials for Monlunabant, which targets the cannabinoid type 1 receptor, regulating appetite and metabolism. (A possible weight loss alternative for patient who can’t tolerate GLP1s or have food addictions).

Icodec, their 1x weekly insulin injection drug is approved in Europe, Japan, and Canada, and likely soon, the US.

Anyone have experience with the oral Semaglutide? While looking for cheaper Glutathione I found a source in India that has Rybelsus in 3mg, 7mg, and 14mg.

 

[penewbie]

Anyone have experience with the oral Semaglutide? While looking for cheaper Glutathione I found a source in India that has Rybelsus in 3mg, 7mg, and 14mg.

I don't have any personal experience with it, but the research shows those dosages suck.

 

[keangkong]

I unfortunately think Novo "disappears" and the stocks continue to tumble due to their us business. Many competitiors with amylin drugs coming eventually and tirz/reta.

They will only be competing on price before too long.

If I was able to accurately predict which stocks would go up and go down, I'd quit my day job and just invest. I follow the investment advice of Jack Bogle, the founder of Vanguard: "Don't look for the needle in the haystack. Just buy the haystack!” In other words, invest in index funds tied to the market as a whole and you'll likely outperform even most professional investors over the long term.